The cancer-immunity cycle provides a framework to understand the series of events that
generate anti-cancer immune responses. It emphasizes the iterative nature of the response …

In cancer patients, dendritic cells (DCs) in tumor-draining lymph nodes can present antigens
to naive T cells in ways that break immunological tolerance. The clonally expanded progeny …

Type 1 conventional dendritic cells (cDC1) can support T cell responses within tumors but
whether this determines protective versus ineffective anti-cancer immunity is poorly …

Dendritic cells (DCs) are a heterogeneous group of antigen-presenting innate immune cells
that regulate adaptive immunity, including against cancer. Therefore, understanding the …

Mutation burden, hypoxia, and immunoediting contribute to altered metabolic profiles in
tumor cells, resulting in a tumor microenvironment (TME) characterized by accumulation of …

Abstract Cancer-specific TCF1+ stem-like CD8+ T cells can drive protective anticancer
immunity through expansion and effector cell differentiation,,–; however, this response is …

Accumulating evidence suggests that metabolic rewiring in malignant cells supports tumour
progression not only by providing cancer cells with increased proliferative potential and an …

Antigen cross‐priming of CD8+ T cells is a critical process necessary for the effective
expansion and activation of CD8+ T cells endowed with the ability to recognize and destroy …

Dendritic cells (DCs) are sentinel immune cells that form a critical bridge linking the innate
and adaptive immune systems. Extensive research addressing the cellular origin and …

Dendritic cells (DCs) are professional antigen-presenting cells that play a key role in
shaping adaptive immunity. DCs have a unique ability to sample their environment, capture …